<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">15056940</PMID>
      <DateCompleted>
        <Year>2004</Year>
        <Month>06</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0015-5691</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>123</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2004</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nihon yakurigaku zasshi. Folia pharmacologica Japonica</Title>
          <ISOAbbreviation>Nihon Yakurigaku Zasshi</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Role of VIP-neurons in the hypothalamic suprachiasmatic nucleus in the control of blood glucose].</ArticleTitle>
        <Pagination>
          <StartPage>253</StartPage>
          <EndPage>260</EndPage>
          <MedlinePgn>253-60</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The hypothalamic suprachiasmatic nucleus (SCN), a master circadian oscillator in mammals, contains VIP-neurons. In our study on the mechanism of the central regulation of glucose metabolism in rats, we obtained following results: 1) intracranial injection of either 2-deoxy-D-glucose (2DG) or VIP elicited hyperglycemia by enhancing neural activities of the sympathetic nerves and by the suppression of the insulin secretion and enhances of secretions of adrenaline and glucagon; 2) bilateral lesions of the SCN eliminated the hyperglycemia and sympathetic excitation induced by intracranial injection of 2DG, and intracranial administration of VIP restored the 2DG-hyperglycemia; 3) infusion of VIP-antisense oligo in the SCN reduced the VIP content in the SCN and abolished the 2DG-hyperglycemia, and intracranial injection of VIP restored the 2DG-hyperglycemia in rats infused the VIP-antisense oligo; 4) intrapancreatic injection of pseudorabies virus (PRV, Bartha), which is retrogradedly transported, caused the transfer of PRV to VIP-neurons in the SCN, and denervations of both the sympathetic and parasympathetic nerves innervating the pancreas eliminated the retrograde transport of PRV to VIP-neurons in the SCN. These findings suggest that VIP-neurons in the SCN regulate the blood glucose level through the enhancement of the sympathetic activity.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nagai</LastName>
            <ForeName>Katsuya</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Protein Metabolism, Institute for Protein Research, Osaka University, Japan. k_nagai@protein.osaka-u.ac.jp</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>jpn</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>Nihon Yakurigaku Zasshi</MedlineTA>
        <NlmUniqueID>0420550</NlmUniqueID>
        <ISSNLinking>0015-5691</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000963">Antimetabolites</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020319">Oligodeoxyribonucleotides, Antisense</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>37221-79-7</RegistryNumber>
          <NameOfSubstance UI="D014660">Vasoactive Intestinal Peptide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-92-5</RegistryNumber>
          <NameOfSubstance UI="D005934">Glucagon</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9G2MP84A8W</RegistryNumber>
          <NameOfSubstance UI="D003847">Deoxyglucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YKH834O4BH</RegistryNumber>
          <NameOfSubstance UI="D004837">Epinephrine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000963" MajorTopicYN="N">Antimetabolites</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017776" MajorTopicYN="N">Autonomic Pathways</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001786" MajorTopicYN="Y">Blood Glucose</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003847" MajorTopicYN="N">Deoxyglucose</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004837" MajorTopicYN="N">Epinephrine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005934" MajorTopicYN="N">Glucagon</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078790" MajorTopicYN="N">Insulin Secretion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020319" MajorTopicYN="N">Oligodeoxyribonucleotides, Antisense</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013493" MajorTopicYN="N">Suprachiasmatic Nucleus</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014660" MajorTopicYN="Y">Vasoactive Intestinal Peptide</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>28</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2004</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2004</Year>
          <Month>6</Month>
          <Day>21</Day>
          <Hour>10</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2004</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15056940</ArticleId>
        <ArticleId IdType="doi">10.1254/fpj.123.253</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
